Scientists report the successful conclusion of Phase I trials of the universal flu vaccine in humans. The universal influenza vaccine is intended to provide protection against all ‘A’ strains of the virus that causes human influenza, including pandemic strains. Therefore, this vaccine will not need to be renewed annually. The vaccine was tested at multiple centers in the US and involved 79 healthy volunteers. The trial results demonstrate that ACAM- FLU-ATM is well tolerated and immunogenic, and no significant side-effects were observed.